Description
The abstract identifies Aβ and tau aggregates as toxins causing aberrant NT release but doesn’t explain the molecular mechanisms. Understanding these pathways is critical for developing targeted synaptic therapies.
Gap type: unexplained_observation Source paper: Gene therapy targeting synaptopathy linked with Alzheimer’s and Parkinson’s disease. (2026, Neuroscience, PMID:41730496)
Resolution criteria
Resolution requires: (1) Synaptosome preparation from APP/PS1 or tau P301L mouse brains shows >=30% reduction in calcium-evoked neurotransmitter release (glutamate, dopamine by HPLC or fluorescent sensor) at plaque-adjacent vs. remote synapses, with Abeta oligomer acute application (100 nM) reproducing the deficit in wild-type synaptosomes; (2) Mechanistic pathway: pull-down or BioID in neurons identifies >=1 presynaptic SNARE or vesicle fusion protein (SNAP-25, synaptotagmin, NSF) directly modified by Abeta oligomers or hyperphosphorylated tau (ubiquitination, S-nitrosylation, or truncation), with site-specific mutation abolishing >=60% of Abeta-induced release inhibition; (3) Functional rescue: single-pathway intervention (SNARE stabilizer, N-methyl maleimide-sensitive factor activator) restores neurotransmitter release to >=80% of control in Abeta-treated neurons. Aggregate-induced cytotoxicity assays without synaptic vesicle-specific mechanistic data are insufficient.